Introduction
toxicity, cancer, deaths, Ovarian carcinoma
CANCER, OVARIAN CARCINOMA
Ovarian carcinoma (OC) accounts for only 2.3% of all new cancer cases in females but it is the fifth leading cause of all cancer-related deaths [We designed this phase III randomized trial to compare a doublet with platinum, i.e. carboplatin and pegylated liposomal doxorubicin-PLD (carboplatin/PLD) with a doublet without platinum, i.e. trabectedin and PLD (trabectedin/PLD) followed by platinum rechallenge at relapse, hypothesizing that this second option might offer an overall survival (OS) benefit.These two chemotherapy regimens have never been directly compared but had shown an interesting efficacy and toxicity profile in previous phase III randomized trials in the recurrent setting [Because of these results the INOVATYON trial was run in patients with recurrent OC and a TFIp 6–12 months; this patient population was deemed “partially platinum sensitive” when the trial was designed and represents about 23% of all OC relapses. This population was considered an approriate clinical setting to explore the hypothesis of increasing platinum efficacy by artificially prolonging the TFIp.